GSK-931145-(11C)

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H30N2O
Molecular Weight	349.4978
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN([11CH3])C1(CCCC1)[C@@H](NC(=O)C2=C(C)C=CC=C2C)C3=CC=CC=C3

InChI

InChIKey=BMXRRRIDMAIEKX-SVZFZNDKSA-N

InChI=1S/C23H30N2O/c1-17-11-10-12-18(2)20(17)22(26)24-21(19-13-6-5-7-14-19)23(25(3)4)15-8-9-16-23/h5-7,10-14,21H,8-9,15-16H2,1-4H3,(H,24,26)/t21-/m0/s1/i3-1

HIDE SMILES / InChI

Molecular Formula	C23H30N2O
Molecular Weight	349.4978
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:55:21 GMT 2025` Edited by `admin` on `Tue Apr 01 16:55:21 GMT 2025`
Record UNII	3GD8XN4ZNE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(11C)GSK-931145

Preferred Name

English

GSK-931145-(11C)

Common Name

English

N-((S)-(1-(DI(METHYL)AMINO)CYCLOPENTYL)-PHENYL-METHYL)-2,6-DIMETHYL-BENZAMIDE

Systematic Name

English

BENZAMIDE, 2,6-DIMETHYL-N-((1-(METHYLMETHYL-11C-AMINO)CYCLOPENTYL)PHENYLMETHYL)-

Systematic Name

English

Code System Code Type Description

CAS

1000022-56-9

Created by admin on Tue Apr 01 16:55:21 GMT 2025 , Edited by admin on Tue Apr 01 16:55:21 GMT 2025

NON-SPECIFIC STEREOCHEMISTRY

MANUFACTURER PRODUCT INFORMATION

GSK-931145-(11C)

Created by admin on Tue Apr 01 16:55:21 GMT 2025 , Edited by admin on Tue Apr 01 16:55:21 GMT 2025

PRIMARY

((11)C)GSK931145 showed good brain penetration and a heterogeneous distribution in agreement with reported GlyT1 localization. Following pretreatment with GSK565710, uptake of ((11)C)GSK931145 was reduced to homogeneous levels. Although ((11)C)GSK565710 also showed good brain penetration and a heterogeneous distribution, the apparent level of specific binding was reduced compared to ((11)C)GSK931145. In contrast, ((11)C)GSK991022 showed a much lower brain penetration and resultant signal following pretreatment with GSK565710. Based on these findings ((11)C)GSK931145 was identified as the most promising ligand for imaging GlyT1 in the porcine brain, possessing good brain penetration, specific signal, and reversible kinetics. ((11)C)GSK931145 is now being progressed into higher species.

PUBCHEM

44253521

Created by admin on Tue Apr 01 16:55:21 GMT 2025 , Edited by admin on Tue Apr 01 16:55:21 GMT 2025

PRIMARY

FDA UNII

3GD8XN4ZNE

Created by admin on Tue Apr 01 16:55:21 GMT 2025 , Edited by admin on Tue Apr 01 16:55:21 GMT 2025

PRIMARY

Related Record Type Details


					3GD8XN4ZNE

GSK-931145-(11C)

ACTIVE MOIETY

Comments:

We report on (11C)GSK931145 as a novel GlyT-1 imaging probe in primate and man. While the distribution and binding potential values were similar across species, both the plasma free fraction (fP: 0.8 vs. 8%) and delivery (K1: 0.025 vs. 0.126 ml cm23 min21) were significantly lower in humans. Test retest reproducibility in humans calculated using a two tissue compartmental model was poor (VAR(VT): 2938%), but was improved using a pseudo reference tissue model (VAR(BPND): 1623%). GSK1018921 EC50 estimates were 22.5 and 45.7 ng/ml in primates and humans, respectively.